ALKERMES | ALKS - Ebitda

Stock Price
34.32
Daily Change
-0.64 -1.83%
Monthly
22.57%
Yearly
9.65%
Q1 Forecast
32.88

ALKERMES reported $121.55M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
AbbVie USD 4.34B 56M Jun/2025
Acadia Pharmaceuticals USD 35.76M 447K Sep/2025
ALKERMES USD 121.55M 4.99M Sep/2025
Amgen USD 5.91B 2.31B Sep/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Gilead Sciences USD 4.03B 628M Sep/2025
Ionis Pharmaceuticals USD -157.12M 307.36M Sep/2025
J&J USD 9.52B 389M Sep/2025
Malin Corporation EUR -1.1M 200K Dec/2024
Merck USD 8.39B 1.97B Sep/2025
Neurocrine Biosciences USD 246.7M 93.8M Sep/2025
Otsuka Holdings JPY 193.79B 59.2B Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025